These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 22109348)
41. Combination therapy of statins and fibrates in the management of cardiovascular risk. Fiévet C; Staels B Curr Opin Lipidol; 2009 Dec; 20(6):505-11. PubMed ID: 19829109 [TBL] [Abstract][Full Text] [Related]
42. Nonstatin therapies for management of dyslipidemia: a review. Sando KR; Knight M Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799 [TBL] [Abstract][Full Text] [Related]
43. Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence. Patch CS; Tapsell LC; Williams PG; Gordon M Vasc Health Risk Manag; 2006; 2(2):157-62. PubMed ID: 17319460 [TBL] [Abstract][Full Text] [Related]
44. Bempedoic acid: Review of a novel therapy in lipid management. Delevry D; Gupta EK Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194 [TBL] [Abstract][Full Text] [Related]
45. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression. Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779 [TBL] [Abstract][Full Text] [Related]
46. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Serban MC; Banach M; Mikhailidis DP Expert Opin Pharmacother; 2016; 17(3):369-80. PubMed ID: 26559810 [TBL] [Abstract][Full Text] [Related]
47. Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. McKenney J Am J Cardiol; 2002 Nov; 90(10B):8K-20K. PubMed ID: 12467936 [TBL] [Abstract][Full Text] [Related]
48. Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. Soran H; Adam S; Durrington PN Atherosclerosis; 2018 Nov; 278():135-142. PubMed ID: 30273874 [TBL] [Abstract][Full Text] [Related]
49. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899 [TBL] [Abstract][Full Text] [Related]
50. State of the art in cholesterol management: targeting multiple pathways. Turley SD Am J Manag Care; 2002 Feb; 8(2 Suppl):S29-32; discussion S45-7. PubMed ID: 11855699 [TBL] [Abstract][Full Text] [Related]
51. Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence. Mascitelli L; Pezzetta F; Goldstein MR Arch Med Res; 2010 Nov; 41(8):649-50. PubMed ID: 21199735 [TBL] [Abstract][Full Text] [Related]
52. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986 [TBL] [Abstract][Full Text] [Related]
53. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. Fleg JL; Mete M; Howard BV; Umans JG; Roman MJ; Ratner RE; Silverman A; Galloway JM; Henderson JA; Weir MR; Wilson C; Stylianou M; Howard WJ J Am Coll Cardiol; 2008 Dec; 52(25):2198-205. PubMed ID: 19095139 [TBL] [Abstract][Full Text] [Related]
54. Lipid management for the prevention of cardiovascular disease. Schaefer JR Curr Pharm Des; 2011; 17(9):852-60. PubMed ID: 21418030 [TBL] [Abstract][Full Text] [Related]
55. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708 [TBL] [Abstract][Full Text] [Related]
56. Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice. Vohnout B; Fábryová Ľ; Klabník A; Kadurová M; Bálinth K; Kozárová M; Bugáňová I; Sirotiaková J; Rašlová K Atherosclerosis; 2018 Oct; 277():323-326. PubMed ID: 30270066 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316 [TBL] [Abstract][Full Text] [Related]
58. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Schectman G; Hiatt J Ann Intern Med; 1996 Dec; 125(12):990-1000. PubMed ID: 8967711 [TBL] [Abstract][Full Text] [Related]
59. Low-density lipoprotein cholesterol: how low can we go? Sherbet DP; Garg P; Brilakis ES; Banerjee S Am J Cardiovasc Drugs; 2013 Aug; 13(4):225-32. PubMed ID: 23609530 [TBL] [Abstract][Full Text] [Related]
60. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins? Goumas GS Angiology; 2009; 60(1):93-8. PubMed ID: 19019838 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]